Arcus Biosciences (NYSE:RCUS) President Juan Jaen Sells 15,764 Shares of Stock

Arcus Biosciences, Inc. (NYSE:RCUS) President Juan Jaen sold 15,764 shares of Arcus Biosciences stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $27.73, for a total value of $437,135.72. Following the transaction, the president owned 897,240 shares of the company’s stock, valued at $24,880,465.20. The trade was a 1.73% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Arcus Biosciences Stock Performance

Shares of RCUS stock opened at $28.74 on Thursday. Arcus Biosciences, Inc. has a 52-week low of $7.91 and a 52-week high of $29.85. The company has a quick ratio of 4.04, a current ratio of 4.04 and a debt-to-equity ratio of 0.19. The stock has a market cap of $3.61 billion, a PE ratio of -9.04 and a beta of 0.85. The business has a 50-day simple moving average of $24.53 and a 200-day simple moving average of $22.92.

Arcus Biosciences (NYSE:RCUS) last posted its earnings results on Tuesday, May 5th. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.10). The company had revenue of $17.00 million for the quarter, compared to analyst estimates of $29.48 million. Arcus Biosciences had a negative return on equity of 68.97% and a negative net margin of 156.36%.The firm’s revenue was down 39.3% on a year-over-year basis. During the same period last year, the business earned ($1.14) earnings per share. On average, equities analysts expect that Arcus Biosciences, Inc. will post -3.66 EPS for the current year.

Wall Street Analysts Forecast Growth

RCUS has been the subject of several recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcus Biosciences in a report on Monday, April 20th. The Goldman Sachs Group raised their price target on shares of Arcus Biosciences from $30.00 to $34.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Wall Street Zen cut shares of Arcus Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Morgan Stanley upped their price objective on shares of Arcus Biosciences from $20.00 to $22.00 and gave the stock an “equal weight” rating in a research report on Monday, May 11th. Finally, Lifesci Capital began coverage on Arcus Biosciences in a research report on Thursday, June 4th. They set an “outperform” rating and a $46.00 target price on the stock. Eight equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Arcus Biosciences currently has an average rating of “Moderate Buy” and an average target price of $35.10.

Institutional Investors Weigh In On Arcus Biosciences

A number of institutional investors have recently added to or reduced their stakes in RCUS. Hantz Financial Services Inc. increased its holdings in Arcus Biosciences by 121.9% in the 4th quarter. Hantz Financial Services Inc. now owns 1,604 shares of the company’s stock worth $38,000 after acquiring an additional 881 shares in the last quarter. T. Rowe Price Investment Management Inc. purchased a new position in Arcus Biosciences during the fourth quarter valued at $39,000. KBC Group NV acquired a new stake in shares of Arcus Biosciences in the first quarter valued at about $50,000. Strs Ohio acquired a new stake in shares of Arcus Biosciences in the first quarter valued at about $67,000. Finally, Tower Research Capital LLC TRC increased its stake in shares of Arcus Biosciences by 184.2% during the second quarter. Tower Research Capital LLC TRC now owns 8,449 shares of the company’s stock worth $69,000 after purchasing an additional 5,476 shares in the last quarter. Institutional investors and hedge funds own 92.89% of the company’s stock.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.